Cardiff ECMC’s vision is to be an internationally recognised centre, significantly contributing to the control and cure of cancer through outstanding translational research, resulting in the development of safe and effective new treatments.
We aim to build on our success to date by expanding our clinical trial resources, while maintaining the quality of our first-rate translational research. We continue to expand our trials portfolio under the leadership of Prof John Chester and Prof Oliver Ottmann, and have an emphasis on bringing new drugs from Cardiff labs to patients in a clinical setting.
Recognising our future needs and long term sustainability, our team expertise is expanding; we have introduced, for the first time, a dedicated Phase 1 project manager to increase connectivity between pre-clinical and clinical aspects of our translational research. We have also recently secured our first ECMC-funded research nurse, who will support Phase 1 trials in both haematological malignancies and solid tumours.
Our ECMC will unite our translational research in both solid tumours and haematological malignancies, bringing together our efforts in shared Focus Areas of common strength - Trials, Stratified Medicine and Drug Development. Examples of key areas of strength include:
Design and delivery of clinical trials
Molecular characterisation of tumours and circulating biomarkers
Evaluation of new drugs for incorporation into national and international multi-centre studies in both solid tumours and blood cancers
We work in close collaboration with key organisations to make our enable our ambitions to become a reality. These organisations include the Velindre Cancer Centre’s Clinical Trial Research Unit, the Wales Cancer Bank, the Wales Cancer Research Centre, Centre for Trials Research: Cancer the Clinical Research Facility and the haematology unit both based at the University Hospital of Wales.
Organisations affiliated with the Cardiff ECMC:
Contact the Centre Manager: